Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults

What Was Tested

This randomized controlled trial paper looks at Liraglutide.

The researchers investigated the effects of liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese non-diabetic individuals.

Why It Was Studied

Mechanisms for liraglutide-induced weight loss are poorly understood.

Who Took Part

The age groups tagged for this paper are teenagers, adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.

Because people in this Liraglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Liraglutide.

Some participants received a placebo instead of Liraglutide, giving a reference point.

Each person switched between Liraglutide and the comparison at some point, usually with a gap in between.

A time span of 5 weeks appears in the methods.

After 5 weeks, 24-h energy expenditure (EE) and substrate oxidation were measured in a respiratory chamber.

Gastric emptying (acetaminophen absorption method), glycemic parameters and appetite were assessed during a 5-h meal test.

Ad libitum energy intake during a subsequent lunch was also assessed.

What Was Measured

The subject headings attached to it are Appetite, Blood Glucose, Body Mass Index, Energy Intake, Energy Metabolism, Gastric Emptying and Glucagon-Like Peptide 1.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Liraglutide over 5 weeks.

Its findings take up roughly 10 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2014 (International journal of obesity (2005)), a journal based in England.

More context: the Liraglutide compound page.